Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7832-7837

  McDonald, J Matthew ^a   Pelioski, Christopher E ^a   Ledoux, Alicia ^a   Sun, Menghong ^a   Raso, Gabriela ^a   Komaki, Ritsuko ^a   Wistuba, Ignacio I ^a   Bekele, B Nebiyou ^a   Aldape, Ken ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B; PROTEIN S6; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UVOMORULIN; CADHERIN; DNA BINDING PROTEIN; RIBOSOME PROTEIN; TTF1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR DIFFERENTIATION; ADENOCARCINOMA; BRAIN TUMOR; CANCER INVASION; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CADHERINS; DNA-BINDING PROTEINS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 59449103857     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0565     Document Type: Article

References (29)

1. American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest1997;111:1710-7.
3. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest 1992;101:1013-8.
4. Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradiation in locally advanced non- small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999;17:2700-9.
5. Mamon HJ, Yeap BY, Janne PA, et al. High risk of brain metastases in surgically staged IIIA non-small- cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005;23:1530-7.
6. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003;34:597-604.
7. Myong NH. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with expressions of p53 and Ki-67 proteins. J Korean Med Sci 2003;18:494-500.
8. Saad RS,Liu YL,Han H, Landreneau RJ,Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol 2004;35:3-7.
9. Miakotina OL, Goss KL, Snyder JM. Insulin utilizes the PI 3-kinase pathway to inhibit SP-A gene expression in lung epithelial cells. Respir Res 2002;3:27.
10. Massion PP,Taflan PM, ShyrY, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004;170:1088-94.
11. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007; 67:6325-32.
12. Hirami Y, Aoe M,Tsukuda K, et al. Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1 a in non-small cell lung cancers. Cancer Lett 2004;214:157-64.
13. David O, Jett J, LeBeau H, et al. Phospho-Akt over- expression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004;10:6865-71.
14. Deeb G, Wang J, Ramnath N, et al. Altered E- cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol 2004;17:430-9.
15. Bubb RS, Komaki R, HachiyaT, et al. Association of Ki-67, p53, and bcl-2 expression of the primary non- small-cell lung cancer lesion with brain metastatic lesion. Int J Radiat Oncol Biol Phys 2002;53:1216-24.
16. Milas I, Komaki R, HachiyaT, et al. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res 2003;9:1070-6.
17. Simmons ML, Lamborn KR,Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glio- blastoma patients. Cancer Res 2001;61:1122-8.
18. Cell Signaling Technology, Inc. [homepage on the Internet]. Danvers (MA); c1999-2008 [updated 2008 Jun 12; cited 2008 Jul 16]. Product Pathways-Translational Control; [about 2 screens]. Available from: http://www.cellsignal.com/products/ 4857.html.
19. Bejarano PA, Mousavi F. Incidence and significance of cytoplasmic thyroid transcription factor-1 immuno- reactivity. Arch Pathol Lab Med 2003;127:193-5.
20. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4: 335-48.
21. Abraham RT. Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 2002;111:9-12.
22. Jacinto E, Hall MN. Tor signaling in bugs, brain and brawn. NatRev MolCellBiol2003;4:117-26.
23. Volarevic S,Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res MolBiol2001;65:101-27.
24. Conde E,Angulo B,Tang M, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 2006;12: 710-7.
25. Pantuck AJ, Seligson DB, KlatteT, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67.
26. Tampellini M, Longo M, Cappia S, et al. Co-expression of EGF receptor, TGFα and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. Virchows Arch 2007; 450:321-8.
27. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006;12:3935-41.
28. Steels E, Paesmans M, BerghmansT, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a metaanalysis. Eur Respir J 2001;18:705-19.
29. Morabia A,Wynder EL Relation ofbronchioloalveo- lar carcinoma to tobacco. BMJ 1992;304:541 -3.